Trade Chinook Therapeutics, Inc. - KDNY CFD

Trading Conditions

• Spread: 0.11
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 40.26
• Open: 40.28
• 1-Year Change: 107.42%
• Day's Range: 40.24 - 40.35

Chinook Therapeutics, Inc. Company profile

About Chinook Therapeutics Inc

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Chinook Therapeutics Inc revenues increased from $827K to $51.6M. Net loss increased 26% to $102.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development-other increase from $24.8M to $66.1M (expense), Change in fair value of contingent consi increase from $1.5M to $27.3M (expense).